St. Jude Downplays ICD Scrutiny Impact, But Jury Is Still Out, Analysts Say
This article was originally published in The Gray Sheet
Executive Summary
During its Jan. 26 earnings call, St. Jude Medical downplayed recent concerns about potential overuse of implantable cardioverter defibrillators as mostly much ado about nothing.
You may also be interested in...
Cardiac Rhythm Management Market Faces Continued Challenges Ahead
The CRM market is facing continued growth challenges as manufacturers struggle to jumpstart lagging sales and broaden adoption of implantable cardioverter defibrillators and cardiac resynchronization therapy devices while facing a brewing storm in the US over appropriate device use.
Cardiac Rhythm Management Market Faces Continued Challenges Ahead
The CRM market is facing continued growth challenges as manufacturers struggle to jumpstart lagging sales and broaden adoption of implantable cardioverter defibrillators and cardiac resynchronization therapy devices while facing a brewing storm in the US over appropriate device use.
Medtronic Plans Company-Wide Layoffs, Restarts Physio-Control Divestiture
Medtronic plans to lay off 4%-5% of its workforce to cut costs and will renew efforts to divest its Physio-Control automated external defibrillator business, the firm announced Feb. 22 in conjunction with its fiscal third-quarter financial results.